MTHFD2 and acute myeloid leukemia: In accordance with this, we found that MTHFD2 inhibitors TH7299 and TH9619 are synergistic when combined with ATR inhibitors VE-821 or VE-822 in both AML HL-60 and THP-1 cells, as well as in bone cancer cell lines U2OS and TC71, increasing apoptosis in a time- and dose-dependent manner (Extended Data Fig. 7).